- Home
- NVVE vs WINT Comparison
NVVE vs WINT Comparison
Compare NVVE & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- WINT
- Stock Information
- Founded
- NVVE 1996
- WINT 1992
- Country
- NVVE United States
- WINT United States
- Employees
- NVVE N/A
- WINT N/A
- Industry
- NVVE Oil Refining/Marketing
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVVE Energy
- WINT Health Care
- Exchange
- NVVE Nasdaq
- WINT Nasdaq
- Market Cap
- NVVE 3.7M
- WINT 3.6M
- IPO Year
- NVVE N/A
- WINT 1995
- Fundamental
- Price
- NVVE $1.19
- WINT $0.57
- Analyst Decision
- NVVE
- WINT Hold
- Analyst Count
- NVVE 0
- WINT 1
- Target Price
- NVVE N/A
- WINT $350.00
- AVG Volume (30 Days)
- NVVE 16.6M
- WINT 264.4K
- Earning Date
- NVVE 05-15-2025
- WINT 05-16-2025
- Dividend Yield
- NVVE N/A
- WINT N/A
- EPS Growth
- NVVE N/A
- WINT N/A
- EPS
- NVVE N/A
- WINT N/A
- Revenue
- NVVE $5,440,777.00
- WINT N/A
- Revenue This Year
- NVVE $892.33
- WINT N/A
- Revenue Next Year
- NVVE N/A
- WINT N/A
- P/E Ratio
- NVVE N/A
- WINT N/A
- Revenue Growth
- NVVE N/A
- WINT N/A
- 52 Week Low
- NVVE $0.82
- WINT $0.55
- 52 Week High
- NVVE $9.35
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- NVVE 50.38
- WINT 26.04
- Support Level
- NVVE $1.19
- WINT $0.67
- Resistance Level
- NVVE $1.40
- WINT $0.81
- Average True Range (ATR)
- NVVE 0.20
- WINT 0.06
- MACD
- NVVE 0.02
- WINT 0.01
- Stochastic Oscillator
- NVVE 37.56
- WINT 5.24
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.